Sunesis Pharmaceuticals (SNSS) Receives News Sentiment Score of 0.29
News headlines about Sunesis Pharmaceuticals (NASDAQ:SNSS) have trended positive this week, according to AlphaOne Sentiment Analysis. The research group, a unit of Accern, rates the sentiment of news coverage by reviewing more than twenty million news and blog sources. AlphaOne ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Sunesis Pharmaceuticals earned a media sentiment score of 0.29 on AlphaOne’s scale. AlphaOne also assigned media coverage about the biopharmaceutical company an impact score of 0 out of 100, indicating that recent news coverage is extremely unlikely to have an impact on the stock’s share price in the near future.
Here are some of the news headlines that may have effected Alpha One’s rankings:
- Sunesis Pharmaceuticals : The Life Sciences Report Examines How Sunesis Pharmaceuticals Shifts Focus to Leukemia Drug (4-traders.com)
- The Cantor Fitzgerald Brokers Raise Earnings Estimates for Sunesis Pharmaceuticals, Inc. (SNSS) – BangaloreWeekly (bangaloreweekly.com)
- NASDAQ:SNSS Shareholder News: Investigation over Potential Wrongdoing at Sunesis Pharmaceuticals, Inc. (digitaljournal.com)
- -$0.76 Earnings Per Share Expected for Sunesis Pharmaceuticals, Inc. (SNSS) This Quarter (americanbankingnews.com)
Shares of Sunesis Pharmaceuticals (NASDAQ:SNSS) traded up 2.540% during trading on Friday, hitting $3.189. The stock had a trading volume of 78,899 shares. The stock has a 50 day moving average of $3.57 and a 200 day moving average of $3.88. The firm’s market cap is $68.44 million. Sunesis Pharmaceuticals has a 52-week low of $2.76 and a 52-week high of $6.30.
Sunesis Pharmaceuticals (NASDAQ:SNSS) last posted its quarterly earnings data on Monday, May 8th. The biopharmaceutical company reported ($0.47) EPS for the quarter, topping the consensus estimate of ($0.83) by $0.36. The firm had revenue of $0.67 million during the quarter, compared to analyst estimates of $1.57 million. Sunesis Pharmaceuticals had a negative net margin of 1,623.12% and a negative return on equity of 806.43%. Sunesis Pharmaceuticals’s revenue was up 4.7% on a year-over-year basis. During the same quarter in the previous year, the business posted ($0.12) EPS. On average, equities analysts anticipate that Sunesis Pharmaceuticals will post ($1.87) EPS for the current year.
SNSS has been the subject of a number of analyst reports. Cantor Fitzgerald reiterated a “hold” rating and set a $3.00 price target on shares of Sunesis Pharmaceuticals in a research note on Tuesday, May 2nd. Zacks Investment Research downgraded Sunesis Pharmaceuticals from a “buy” rating to a “hold” rating in a research note on Wednesday, March 15th.
About Sunesis Pharmaceuticals
Sunesis Pharmaceuticals, Inc is a biopharmaceutical company. The Company focuses on the development and commercialization of its pipeline of oncology therapeutics for the treatment of solid and hematologic cancers. The Company offers QINPREZO (vosaroxin), which is a product candidate for the treatment of acute myeloid leukemia (AML).
Receive News & Stock Ratings for Sunesis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sunesis Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.